A 2026 update on myelodysplastic neoplasms: current state, challenges and future directions

A comprehensive review published in Nature Reviews Clinical Oncology provides a 2026 update on myelodysplastic neoplasms (MDS), a heterogeneous group of blood cancers characterized by ineffective blood cell production and a risk of progression to acute myeloid leukemia. The authors report that the epidemiological burden of MDS appears to be rising and detail recent advances in diagnosis, molecular risk stratification, and clinical management strategies. The review synthesizes the current state of the field, highlighting both the progress made in understanding MDS biology and the persistent challenges that remain in optimizing patient outcomes. This authoritative overview from a top-tier journal is expected to serve as an important reference for hematologic oncologists navigating an increasingly complex treatment landscape.